Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JYP0035 in advanced solid tumors
NCT06158477Phase 1Recruiting
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JYP0035 in solid tumor (advanced stage) (2 cohorts), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Adverse event rate. Started Jan 2024; status: recruiting.
02
Drugs
JYP0035
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06158477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158477.